Clinical Trials Browser

INDUSTRY × Lymphoma, Mantle-Cell × Cyclophosphamide × Clear all

NCT06564038 2026-05-14

Soundtrack-E

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07569965 2026-05-06

FRONTIER

Phase 2 Not yet recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02601313 2026-03-18

ZUMA-2

Phase 2 Completed

105 enrolled 33 charts 1 FDA

Lymphoma, Mantle-Cell

NCT06253663 2025-12-16

JKART-1

Phase 2 Active not recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT06285422 2025-11-28

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04880434 2025-11-17

ZUMA-2

Phase 2 Completed

Lymphoma, Mantle-Cell

NCT05878184 2025-10-02

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04735471 2025-06-18

GLEAN-1

Phase 1 Terminated

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT05665062 2025-04-06

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05934097 2023-07-06

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04323657 2023-03-16

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Phase 1/2 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05155215 2021-12-13

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Phase 1/2 Unknown

Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, Mantle-Cell

NCT04162756 2021-10-14

ZUMA-18

Approved for marketing

Recurrence, Lymphoma, Mantle-Cell

NCT00722137 2018-07-12

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 3 Completed

487 enrolled 20 charts

Lymphoma, Mantle-Cell

NCT00877006 2018-02-05

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Phase 3 Completed

447 enrolled 24 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT00022945 2005-06-24

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Phase 2 Completed

Lymphoma, Mantle-Cell